Denosumab
- PDF / 170,622 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 45 Downloads / 159 Views
1 S
Hypocalcaemia: case report. A 59-year-old woman developed hypocalcaemia during treatment with denosumab for osteoporosis. The post-menopausal woman was admitted due to hypocalcaemia. She was also found to have hypophosphataemia and hypomagnesaemia [aetiology not stated]. Her medical history was significant for bariatric Billroth-II gastric bypass surgery 15 years ago, barrett esophagus, rheumatoid arthritis, osteoporosis, paroxysmal atrial fibrillation, and pericarditis associated with suspected rheumatologic disease status, for which she had undergone a pericardial window surgery 3 years before. Additionally, she was also found to have amiodarone-induced hypothyroidism. At admission, She had been receiving denosumab since last 3 months for osteoporosis [dosage and route not stated]. Her regular home medications included calcium citrate and ergocalciferol. She also reported that, she was compliant with her medications. However, she took low dose of calcium for the last 4 days while she was on a vacation, due to unavailability of the medication. She had been experiencing intermittent tingling in her feet, hands and perioral region and fatigue from the last 2–3 days. At admission, she was afebrile with unremarkable vital signs and physical examination. She had a positive Chvostek’s sign. Blood work revealed calcium 5.8 mg/dL (corrected calcium was 6.0 mg/dL and ionised calcium was 0.8 mg/dL) with phosphorus
Data Loading...
